Charles Schwab Investment Management Inc. Acquires 32,311 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Charles Schwab Investment Management Inc. lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 515,222 shares of the medical research company's stock after acquiring an additional 32,311 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.01% of Charles River Laboratories International worth $101,483,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Hilton Capital Management LLC grew its holdings in Charles River Laboratories International by 17.4% during the 3rd quarter. Hilton Capital Management LLC now owns 7,658 shares of the medical research company's stock worth $1,508,000 after acquiring an additional 1,135 shares during the last quarter. Prospera Private Wealth LLC bought a new stake in shares of Charles River Laboratories International in the third quarter worth $168,000. Premier Fund Managers Ltd increased its holdings in Charles River Laboratories International by 56.3% in the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock valued at $49,573,000 after purchasing an additional 90,000 shares during the period. Swiss National Bank raised its position in Charles River Laboratories International by 0.5% during the 3rd quarter. Swiss National Bank now owns 152,800 shares of the medical research company's stock worth $30,097,000 after purchasing an additional 700 shares during the last quarter. Finally, Mizuho Securities USA LLC lifted its holdings in Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock worth $19,081,000 after buying an additional 92,895 shares during the period. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $197.75 on Wednesday. The company has a market cap of $10.11 billion, a P/E ratio of 24.75, a PEG ratio of 5.05 and a beta of 1.38. The company has a fifty day simple moving average of $194.94 and a 200 day simple moving average of $205.44. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. During the same period last year, the company earned $2.72 earnings per share. The business's revenue was down 1.6% on a year-over-year basis. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its stock is undervalued.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on CRL shares. The Goldman Sachs Group reduced their target price on Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $270.00 to $205.00 in a report on Thursday, August 8th. UBS Group increased their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. TD Cowen boosted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Finally, Barclays decreased their target price on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a research note on Thursday, August 8th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $214.38.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).